Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.61 |
| ▸ | MAOA | P21397 | 3/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15511597 | 0.98 | MAOB (0.59) | MAOBMAOACYP19A1SIGMAR1HRH1 | |
| SCHEMBL26081845 | 0.98 | MAOB (0.59) | MAOBMAOACYP19A1SIGMAR1HRH1 | |
| SCHEMBL29961815 | 0.98 | MAOB (0.59) | MAOBMAOACYP19A1SIGMAR1HRH1 | |
| SCHEMBL951868 | 0.94 | MAOA (0.63) | MAOBMAOACYP19A1SIGMAR1CYP3A4 | |
| Hydrochloric Acid SCHEMBL25231681 | 0.92 | MAOA (0.64) | MAOBMAOACYP19A1SIGMAR1CYP3A4 | |
| SCHEMBL29436975 | 0.91 | MAOB (0.71) | MAOBMAOACYP19A1SIGMAR1CYP3A4 | |
| SCHEMBL18045550 | 0.91 | MAOB (0.71) | MAOBMAOACYP19A1SIGMAR1CYP3A4 | |
| SCHEMBL28770903 | 0.89 | MAOB (0.68) | MAOBMAOACYP19A1SIGMAR1CYP3A4 | |
| SCHEMBL30637158 | 0.89 | MAOB (0.68) | MAOBMAOACYP19A1SIGMAR1CYP3A4 | |
| SCHEMBL30211975 | 0.89 | MAOB (0.68) | MAOBMAOACYP19A1SIGMAR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035513-A1 | RESIN COMPOSITION, REINFORCED COMPOSITE MATERIAL, SHAPED PRODUCT, AND METHOD OF RECOVERING REINFORCING FIBER FROM REINFORCED COMPOSITE MATERIAL | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2026-02-05 | — | — | US | disclosed |
| EP-4578892-A1 | RESIN COMPOSITION, COMPOSITE REINFORCING MATERIAL, MOLDED BODY, AND METHOD FOR RECOVERING REINFORCING FIBERS FROM COMPOSITE REINFORCING MATERIAL | Asahi Kasei Kabushiki Kaisha (JP) | 2025-07-02 | — | — | EP | disclosed |
| CN-120051729-A | Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal display element | 日产化学株式会社 | 2025-05-27 | — | — | CN | disclosed |
| CN-119620472-A | Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element using same | 日产化学株式会社 | 2025-03-14 | — | — | CN | disclosed |
| CN-112602014-B | Method for producing liquid crystal alignment film, and liquid crystal display element | 日产化学株式会社 | 2025-02-11 | — | — | CN | disclosed |
| CN-112639595-B | Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal display element | 日产化学株式会社 | 2025-01-10 | — | — | CN | disclosed |
| CN-111683986-B | Composition for forming cured film, alignment material, and retardation material | 日产化学株式会社 | 2025-01-10 | — | — | CN | disclosed |
| CN-113272729-B | Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal display element | 日产化学株式会社 | 2024-08-20 | — | — | CN | disclosed |
| CN-113316742-B | Liquid crystal aligning agent, liquid crystal alignment film, liquid crystal display element, and novel monomer | 日产化学株式会社 | 2024-08-16 | — | — | CN | disclosed |
| CN-118235084-A | Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal display element | 日产化学株式会社 | 2024-06-21 | — | — | CN | disclosed |
| WO-2023085390-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | 日産化学株式会社 | 2023-05-19 | — | — | WO | disclosed |
| CN-115975155-A | Composition for forming cured film for alignment material, and retardation material | 日产化学株式会社 | 2023-04-18 | — | — | CN | disclosed |
| US-11456184-B2 | Substrate processing method and substrate processing system | TOKYO ELECTRON LIMITED (JP) | 2022-09-27 | — | — | US | disclosed |
| US-20210125837-A1 | SUBSTRATE PROCESSING METHOD AND SUBSTRATE PROCESSING SYSTEM | TOKYO ELECTRON LIMITED (JP) | 2021-04-29 | — | — | US | disclosed |
| WO-2020145175-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | 日産化学株式会社 | 2020-07-16 | — | — | WO | disclosed |
| WO-2020138259-A1 | LIQUID CRYSTAL ALIGNING AGENT, LIQUID CRYSTAL ALIGNMENT FILM, LIQUID CRYSTAL DISPLAY ELEMENT, AND NOVEL MONOMER | 日産化学株式会社 | 2020-07-02 | — | — | WO | disclosed |
| US-9447240-B2 | Polyimide precursor modified with dicarboxylic acid anhydride, imidized polyimide and liquid crystal aligning agent using it | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-20140066590-A1 | POLYIMIDE PRECURSOR MODIFIED WITH DICARBOXYLIC ACID ANHYDRIDE, IMIDIZED POLYIMIDE AND LIQUID CRYSTAL ALIGNING AGENT USING IT | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-03-06 | — | — | US | disclosed |
| EP-0596802-B1 | Erythromycin derivatives, their process of preparation and their application as medicaments | ROUSSEL UCLAF (FR) | 1996-03-20 | — | — | EP | disclosed |
| EP-0596802-A1 | Erythromycin derivatives, their process of preparation and their application as medicaments | ROUSSEL UCLAF (FR) | 1994-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066590-A1 | POLYIMIDE PRECURSOR MODIFIED WITH DICARBOXYLIC ACID ANHYDRIDE, IMIDIZED POLYIMIDE AND LIQUID CRYSTAL ALIGNING AGENT USING IT | CCDC22, RCC1, MACF1 | MAOB 4432/4885MAOA 4410/4885CYP19A1 2665/4885 |
| US-20260035513-A1 | RESIN COMPOSITION, REINFORCED COMPOSITE MATERIAL, SHAPED PRODUCT, AND METHOD OF RECOVERING REINFORCING FIBER FROM REINFORCED COMPOSITE MATERIAL | TAF1, TAF1L, TAF9 | MAOB 2358/4885MAOA 1110/4885CYP19A1 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.